High-Throughput and High-Sensitivity Biomarker Monitoring in Body Fluid by Fast LC SureQuant IS-Targeted Quantitation.

Autor:	Kalogeropoulos K; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark. Electronic address: konka@dtu.dk., Savickas S; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark., Haack AM; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark., Larsen CA; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark., Mikosiński J; Poradnia Chorób Naczyń Obwodowych 'MIKOMED', Łódź, Poland., Schoof EM; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark., Smola H; Paul Hartmann AG, Heidenheim, Germany., Bundgaard L; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark. Electronic address: loubun@anivet.au.dk., Auf dem Keller U; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark.
Jazyk:	angličtina
Zdroj:	Molecular & cellular proteomics : MCP [Mol Cell Proteomics] 2024 Oct 22; Vol. 23 (12), pp. 100868. Date of Electronic Publication: 2024 Oct 22.
DOI:	10.1016/j.mcpro.2024.100868
Abstrakt:	Targeted proteomics methods have been greatly improved and refined over the last decade and are becoming increasingly the method of choice in protein and peptide quantitative assays. Despite the tremendous progress, targeted proteomics assays still suffer from inadequate sensitivity for lower abundant proteins and throughput, especially in complex biological samples. These attributes are essential for establishing targeted proteomics methods at the forefront of clinical use. Here, we report an assay utilizing the SureQuant internal standard-triggered targeted method on a latest generation mass spectrometer coupled with an EvoSep One liquid chromatography platform, which displays high sensitivity and a high throughput of 100 samples per day. We demonstrate the robustness of this method by quantifying proteins spanning six orders of magnitude in human wound fluid exudates, a biological fluid that exhibits sample complexity and composition similar to plasma. Among the targets quantified were low-abundance proteins such at tumor necrosis factor A and interleukin 1-β, highlighting the value of this method in the quantification of trace amounts of invaluable biomarkers that were until recently hardly accessible by targeted proteomics methods. Taken together, this method extends the toolkit of targeted proteomics assays and will help to drive forward mass spectrometry-based proteomics biomarker quantification. Competing Interests: Conflicts of Interest H. S. is a full-time employee of HARTMANN. The other authors declare no competing interests. (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu